| Home | E-Submission | Sitemap | Contact Us |  
Korean Journal of Clinical Oncology > Article
Korean J Clin Oncol. 2010;6(1): 7-18.         doi: https://doi.org/10.14216/kjco.10002
Targeted therapies in metastatic colorectal cancer
Seong Taek Oh
Catholic University of Korea Seoul St. Mary's Hospital
전이성 결장직장암에서 표적치료
서울 성모병원 대장 항문외과
Corresponding Author: Seong Taek Oh ,Tel: +82-2-2258-6100, Fax: +82-2-595-2822, Email: stoh@catholic.ac.kr
Received: May 20, 2010;  Accepted: June 23, 2010.
Share :  
Treatment of colorectal cancer (CRC) has developed considerably over the past 10 years, especially in the areas of targeted therapeutics and biomarker development. Targeted therapies, which include monoclonal antibodies and small molecule inhibitors, directed at the vascular endothelial growth factor pathway and the epidermal growth factor pathway are now key players in the treatment of colorectal cancer. Preclinical and clinical studies have shown that the epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) are valid therapeutic targets for patients with CRC. This review focuses on the evidence supporting the current role of targeted therapy and the strategy of combining chemotherapy and biological therapy in the treatment of metastatic colorectal cancer.
Keywords: metastatic colorectal cancer | targeted therapy
Editorial Office
101-3304 Brownstone Seoul, 464 Cheongpa-ro, Jung-gu, Seoul 04510, Korea
TEL : +82-2-393-2114   FAX : +82-2-393-1649   E-mail : ksco2004@daum.net

Copyright© Korean Society of Surgical Oncology.                Developed in M2PI
About |  Browse Articles |  Current Issue |  For Authors and Reviewers